STAT+: Pharmalittle: Big pharma maps legal strategy against U.S. drug pricing reform; U.S. pharma layoffs continue to climb
The number of layoffs in the U.S. pharmaceutical industry continued at a brisk rate last month as another 600 jobs were eliminated.
Top of the morning to you, and a fine one it is. The sun is peeking through clouds hovering above the Pharmalot campus, birds are chirping in nearby pin oaks and the official mascot is bounding about the grounds with a playmate. As for us, we are brewing the usual cups of stimulation — our choice today is chocolate cappuccino — as we brace ourselves for tackling the growing to-do list. No doubt, you can relate. So time to get cracking. Once again, we have compiled a menu of tidbits to help you on your journey, which we hope will bring to you a pleasant destination by the time today is over. And of course, do keep in touch. We enjoy hearing your secrets …
Some of the world’s biggest drugmakers are laying legal groundwork to fight the U.S. plan to negotiate drug prices for its Medicare health coverage, including the argument that a ban against speaking about these talks violates constitutional rights, Reuters reports. The Biden administration’s drug pricing reform, part of the Inflation Reduction Act, aims to save $25 billion through price negotiations by 2031 for Americans who pay more for medicines than any other country. But the pharmaceutical industry says the law, passed last year, will result in a loss of profits that will force them to pull back on developing groundbreaking new treatments.
What's Your Reaction?
